Ysios Capital

Ysios Capital, established in 2008, is a prominent Spanish independent venture capital firm. It specializes in providing private equity financing to early and mid-stage life science companies, focusing on those developing innovative therapeutic products and platform technologies. With approximately €350 million under management across three dedicated funds, Ysios Capital supports companies across the entire healthcare and biotechnology spectrum, with a particular emphasis on pharmaceuticals, diagnostics, and medical devices. The firm is led by a team with extensive experience in building biotech companies.

Thomas Harth

Principal

Guillem Laporta

Partner

Joel Jean Mairet

Managing Partner and Co - Founder

Raul Martin

Partner

Jordi Xiol

Partner

73 past transactions

Neurona Therapeutics

Venture Round in 2025
Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.

Adcendo

Series B in 2024
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Adcendo

Series A in 2024
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Memo Therapeutics

Series C in 2024
Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Engrail Therapeutics

Series B in 2024
Engrail Therapeutics, Inc. is dedicated to developing and commercializing neuro drugs aimed at treating diseases of the nervous system. Founded in 2019 and based in San Diego, California, the company focuses on creating transformative medicines to alleviate the significant burden of such conditions. One of its key products is ENX-101, a preclinical compound designed to modulate a receptor for GABA, a critical neurotransmitter in the brain. Engrail Therapeutics combines biological insights with clinically meaningful solutions to advance its portfolio of therapies, utilizing a flexible transaction model to efficiently progress its drug candidates from development to commercialization.

Neurona Therapeutics

Series E in 2024
Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.

Kynexis

Series A in 2023
Kynexis is focused on developing a precision medicine aimed at treating cognitive impairment associated with schizophrenia (CIAS). The company's innovative research utilizes a human biology-based approach to identify causal biomarkers that inform its mechanism of action during clinical development. Additionally, Kynexis employs a human genetics strategy to pinpoint specific sub-populations of patients who are likely to respond positively to the treatment. Through these methods, Kynexis seeks to enhance brain function in individuals affected by schizophrenia, addressing a critical need in mental health care.

Xeltis

Series D in 2023
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Tagworks Pharmaceuticals

Series A in 2023
Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

VarmX

Series B in 2023
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Adcendo

Series A in 2023
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

SparingVision

Series B in 2022
SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Mineralys Therapeutics

Series B in 2022
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Minoryx Therapeutics

Series C in 2022
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Splice Bio

Series A in 2022
Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

NorthSea Therapeutics

Series C in 2021
NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Aura Biosciences

Post in 2021
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Aelix Therapeutics

Venture Round in 2021
Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for the treatment of HIV infection. Established in 2015, Aelix Therapeutics emerged as a spin-off from HIVACAT, a Catalan initiative aimed at creating effective HIV vaccines. The company is led by a team of experienced professionals in the fields of HIV and biotechnology, including Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell, and Jordi Naval. Aelix Therapeutics leverages innovative immunogen designs to enhance its therapeutic approaches and has established partnerships that provide access to extensive cohorts of HIV-infected patients across various continents, facilitating clinical research and development. The company's vaccine strategy is based on a T-cell immunogen that has the potential to elicit strong immune responses, aiming to transform the treatment landscape for HIV and improve patient outcomes.

Cytoki Pharma

Series A in 2021
CytoKi Pharma ApS is a discovery-stage biotechnology company based in Værløse, Denmark, founded in 2019. The company focuses on developing innovative treatments for diseases with significant unmet medical needs, particularly those resulting from epithelial injury. CytoKi Pharma is currently in the pre-clinical stage and is advancing its lead program, which involves an engineered long-acting IL-22 protein licensed from a major pharmaceutical entity. IL-22 is a crucial cytokine that plays a vital role in the immune system's response to tissue injury, acting as a signal for survival and recovery. By harnessing the therapeutic potential of this modified IL-22 protein, CytoKi Pharma aims to address the challenges posed by organ injuries and improve patient outcomes in affected populations.

Adcendo

Series A in 2021
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Synendos Therapeutics

Series A in 2021
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.

Aura Biosciences

Venture Round in 2021
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

CorWave

Series C in 2021
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

SparingVision

Venture Round in 2020
SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Galecto

Series D in 2020
Galecto is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to address severe diseases, particularly fibrosis and cancer. Established in 2011, Galecto builds on over a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company's lead product candidate, GB0139, is an inhaled galectin-3 inhibitor specifically designed for treating severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. Additionally, Galecto is advancing GB1211, an oral selective galectin-3 inhibitor aimed at addressing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto leverages its unique therapeutic platform to target the underlying biological processes associated with fibrosis and related diseases.

Lava Therapeutics

Series C in 2020
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Splice Bio

Venture Round in 2020
Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

VarmX

Series B in 2020
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Ona Therapeutics

Series A in 2020
Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. The company focuses on the discovery and development of therapeutic biologics aimed at targeting tumor metastatic-initiating cells and lipid metabolism. Ona Therapeutics develops therapies that block fat metabolism pathways in animal models of cancer and inhibit cells responsible for metastasis. This approach holds the potential to prevent the development of malignant tumors and eliminate existing ones, allowing healthcare institutions to address various metastatic cancers, including those of the oral cavity, breast, ovary, stomach, bladder, prostate, and melanoma.

AM Pharma

Venture Round in 2020
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Anaconda Biomed

Series B in 2019
Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.

AM Pharma

Series F in 2019
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

SANIFIT

Series D in 2019
Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

CVRx

Series G in 2019
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Galecto

Series C in 2018
Galecto is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to address severe diseases, particularly fibrosis and cancer. Established in 2011, Galecto builds on over a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company's lead product candidate, GB0139, is an inhaled galectin-3 inhibitor specifically designed for treating severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. Additionally, Galecto is advancing GB1211, an oral selective galectin-3 inhibitor aimed at addressing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto leverages its unique therapeutic platform to target the underlying biological processes associated with fibrosis and related diseases.

Minoryx Therapeutics

Series B in 2018
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Rainier Therapeutics

Series B in 2018
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

Aura Biosciences

Series C in 2017
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Xeltis

Series C in 2017
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Babyscripts

Series A in 2017
Babyscripts is a developer of a virtual maternity care platform aimed at enhancing prenatal and postpartum care for pregnant mothers. The company's three-tiered approach allows healthcare providers to deliver tailored, risk-specific care anytime and anywhere. The first tier features a mobile app that offers daily educational content and resources throughout pregnancy and the postpartum period. The second tier incorporates remote monitoring through medical devices, enabling patients to track health metrics like blood pressure and alerting providers to potential risks. This system facilitates the transition of care beyond traditional clinical settings, enabling providers to focus on higher-risk patients while automating routine care. The third tier fosters collaboration between care teams and insurers, addressing challenges in care coordination and access, ultimately improving health outcomes and reducing costs. Through its innovative platform, Babyscripts aims to eliminate maternal mortality and enhance access to quality care for all mothers.

Anaconda Biomed

Series A in 2017
Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.

Vivet Therapeutics

Series A in 2017
Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.

Rainier Therapeutics

Series B in 2017
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

MedLumics

Series B in 2017
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Prexton Therapeutics

Series B in 2017
Prexton Therapeutics is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It focuses on developing innovative drugs for Parkinson's disease and other brain disorders, utilizing a unique scientific approach that integrates molecular, behavioral, and chemistry technologies. The company targets metabotropic glutamate receptors, specifically mGluR4 and mGluR3, to create novel therapeutic compounds. Prexton Therapeutics aims to enhance the quality of life for patients by providing alternatives to traditional dopaminergic treatments, enabling quicker initiation of therapy and improved medical outcomes. As of March 2018, Prexton operates as a subsidiary of H. Lundbeck A/S.

OxThera

Series D in 2016
OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

CorWave

Series B in 2016
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

STAT-Dx

Series C in 2016
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

Inbiomotion

Series B in 2016
Inbiomotion is dedicated to the development and commercialization of a biomarker that predicts metastasis, with the aim of enhancing the quality of life for breast cancer patients through personalized adjuvant treatment. Established in 2010 as a spin-off from IRB Barcelona and ICREA, the company has created a diagnostic assay based on a highly selective single-gene biomarker. This biomarker has shown promise in identifying early-stage breast cancer patients who are likely to benefit from bisphosphonate adjuvant treatment, potentially improving their overall survival and reducing the risk of invasive disease. Additionally, the biomarker can predict the likelihood of metastases relapse from primary tumors at an early stage, positioning Inbiomotion to advance clinical practices in personalized medicine for breast cancer care.

Aelix Therapeutics

Series A in 2016
Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for the treatment of HIV infection. Established in 2015, Aelix Therapeutics emerged as a spin-off from HIVACAT, a Catalan initiative aimed at creating effective HIV vaccines. The company is led by a team of experienced professionals in the fields of HIV and biotechnology, including Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell, and Jordi Naval. Aelix Therapeutics leverages innovative immunogen designs to enhance its therapeutic approaches and has established partnerships that provide access to extensive cohorts of HIV-infected patients across various continents, facilitating clinical research and development. The company's vaccine strategy is based on a T-cell immunogen that has the potential to elicit strong immune responses, aiming to transform the treatment landscape for HIV and improve patient outcomes.

Minoryx Therapeutics

Series A in 2015
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

DermaLumics

Venture Round in 2015
DermaLumics is a global medical device company that specializes in advanced optical coherence tomography (OCT) technology, aimed at enhancing skincare through innovative imaging solutions. The company has developed a handheld diagnostic device designed to assist dermatologists in the minimally invasive diagnosis of skin cancer. This technology not only aids in the early detection of skin-related issues but also enables patients to better maintain the health of their skin, hair, and nails. By focusing on these advanced imaging capabilities, DermaLumics seeks to transform the way skincare is approached and managed in the medical field.

SANIFIT

Series C in 2015
Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Aura Biosciences

Series B in 2015
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Prexton Therapeutics

Series A in 2015
Prexton Therapeutics is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It focuses on developing innovative drugs for Parkinson's disease and other brain disorders, utilizing a unique scientific approach that integrates molecular, behavioral, and chemistry technologies. The company targets metabotropic glutamate receptors, specifically mGluR4 and mGluR3, to create novel therapeutic compounds. Prexton Therapeutics aims to enhance the quality of life for patients by providing alternatives to traditional dopaminergic treatments, enabling quicker initiation of therapy and improved medical outcomes. As of March 2018, Prexton operates as a subsidiary of H. Lundbeck A/S.

AM Pharma

Series E in 2014
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Kala Pharmaceuticals

Series B in 2014
Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Endosense

Series C in 2013
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

CVRx

Series F in 2013
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

STAT-Dx

Series B in 2013
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

Endosense

Series C in 2012
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

Inbiomotion

Series A in 2012
Inbiomotion is dedicated to the development and commercialization of a biomarker that predicts metastasis, with the aim of enhancing the quality of life for breast cancer patients through personalized adjuvant treatment. Established in 2010 as a spin-off from IRB Barcelona and ICREA, the company has created a diagnostic assay based on a highly selective single-gene biomarker. This biomarker has shown promise in identifying early-stage breast cancer patients who are likely to benefit from bisphosphonate adjuvant treatment, potentially improving their overall survival and reducing the risk of invasive disease. Additionally, the biomarker can predict the likelihood of metastases relapse from primary tumors at an early stage, positioning Inbiomotion to advance clinical practices in personalized medicine for breast cancer care.

MedLumics

Series A in 2011
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

AM Pharma

Series D in 2011
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

STAT-Dx

Series A in 2011
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

Cardoz

Series A in 2010
Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.

Sabirmedical

Venture Round in 2010
SabirMedical S.L. is a biomedical research and development company based in Barcelona, Spain, founded in 2007. The company specializes in developing innovative technologies for diagnostics and patient care, particularly in the area of cardiovascular monitoring. Its offerings include non-invasive blood pressure monitoring systems that utilize pulse oximetry, designed for hospital, ambulatory, and home use. SabirMedical operates from the Bioincubator PCB-Santander space at Barcelona Science Park, emphasizing its commitment to advancing healthcare through technology.

Cellerix

Series C in 2010
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.

Cellerix

Series B in 2009
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.

Endosense

Series B in 2009
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

BioVex Group

Venture Round in 2009
BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

Cellerix

Series B in 2007
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.

TiGenix

Venture Round in 2003
TiGenix NV is a Belgium-based biomedical company specializing in innovative treatments for damaged and osteoarthritic joints. Founded as a spin-off from the Catholic University of Leuven and the University of Ghent, TiGenix leverages regenerative medicine to create durable therapies validated through controlled clinical studies. The company focuses on developing a portfolio of products aimed at addressing specific musculoskeletal issues, with a primary emphasis on cartilage damage, which significantly impairs patient mobility and function. TiGenix also explores the anti-inflammatory properties of stem cells to create novel therapies for serious medical conditions, particularly in areas where there is a high unmet medical need.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.